- Category : Healthcare
- Region : Europe
- Publishing Date : 06/30/2022
Europe Ophthalmic Drug Delivery System Market 2021-2031 by Product (Syringes, Eyedroppers, Dispensers, Sprayers, Contact Lenses, Inserts, Implants, Plugs), Dosage Form (Solutions, Gels, Ointments, Suspensions, Emulsions, Liposomes & Nanoparticles), Disease (Glaucoma, Diabetic Retinopathy, Cataract, Dry Eye Syndrome, Macular Degeneration, Diabetic Macular Edema, Refractive Issues), Setting (Hospitals, Clinics, Homecare Settings, ASCs, Others), and Country: Trend Forecast and Growth Opportunity
Europe ophthalmic drug delivery system market was valued at $3,856.3 million in 2021 and will grow by 6.4% annually over 2021-2031, driven by the growing prevalence of ophthalmic diseases, the emerging novel ocular drug delivery systems, rise in number of ophthalmic procedures that require attentive post procedural care, and the increasing demand to deliver controlled dosage forms for pediatric and geriatric population.
Highlighted with 30 tables and 57 figures, this 127-page report “Europe Ophthalmic Drug Delivery System Market 2021-2031 by Product (Syringes, Eyedroppers, Dispensers, Sprayers, Contact Lenses, Inserts, Implants, Plugs), Dosage Form (Solutions, Gels, Ointments, Suspensions, Emulsions, Liposomes & Nanoparticles), Disease (Glaucoma, Diabetic Retinopathy, Cataract, Dry Eye Syndrome, Macular Degeneration, Diabetic Macular Edema, Refractive Issues), Setting (Hospitals, Clinics, Homecare Settings, ASCs, Others), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe ophthalmic drug delivery system market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Europe ophthalmic drug delivery system market in every aspect of the classification from perspectives of Product, Dosage Form, Disease, Setting, and Country.
Based on Product, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Pre-filled Syringes
• Multidose Eyedroppers
• Squeeze Dispensers
• Mist Sprayers
• Contact Lenses
• Ocular Inserts
• Intraocular Implants
• Punctal Plugs
• Other Products
Based on Dosage Form, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Solutions
• Gels
• Ointments
• Suspensions
• Emulsions
• Liposomes & Nanoparticles
By Disease, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Glaucoma
• Diabetic Retinopathy
• Cataract
• Dry Eye Syndrome
• Macular Degeneration
• Diabetic Macular Edema
• Refractive Issues
• Other Diseases
By Setting, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Hospitals
• Clinics
• Homecare Settings
• Ambulatory Surgical Centers (ASCs)
• Other Settings
Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Netherlands
• Rest of Europe (further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Product, Dosage Form, and Setting over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Aero Pump GmbH
Allergan plc.
AptarGroup, Inc.
Becton, Dickinson and Company
Biocorp
Clearside Biomedical, Inc.
EyePoint Pharmaceuticals, Inc.
Gaplast GmbH
Gerresheimer AG
Jotteq Inc.
Kedalion Therapeutics, Inc.
Mati Therapeutics, Inc.
Nemera
Nipro Corporation
Ocular Therapeutix, Inc.
Ocumedic, Inc.
Owen Mumford
Re-Vana Therapeutics
Silgan Holdings Inc.
Terumo Corporation
Valeant Pharmaceuticals International Inc. (Bausch Health Company)
West Pharmaceutical Services, Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
List of Tables:
Table 1. Snapshot of Europe Ophthalmic Drug Delivery System Market in Balanced Perspective, 2021-2031 17
Table 2. World Economic Outlook, 2021-2031 22
Table 3. Main Product Trends and Market Opportunities in Europe Ophthalmic Drug Delivery System Market 32
Table 4. Europe Ophthalmic Drug Delivery System Market by Product, 2021-2031, $ mn 40
Table 5. Europe Ophthalmic Drug Delivery System Market by Dosage Form, 2021-2031, $ mn 51
Table 6. Europe Ophthalmic Drug Delivery System Market by Disease, 2021-2031, $ mn 59
Table 7. Europe Ophthalmic Drug Delivery System Market by Setting, 2021-2031, $ mn 69
Table 8. Europe Ophthalmic Drug Delivery System Market by Country, 2021-2031, $ mn 78
Table 9. Germany Ophthalmic Drug Delivery System Market by Product, 2021-2031, $ mn 81
Table 10. Germany Ophthalmic Drug Delivery System Market by Dosage Form, 2021-2031, $ mn 81
Table 11. Germany Ophthalmic Drug Delivery System Market by Setting, 2021-2031, $ mn 82
Table 12. U.K. Ophthalmic Drug Delivery System Market by Product, 2021-2031, $ mn 84
Table 13. U.K. Ophthalmic Drug Delivery System Market by Dosage Form, 2021-2031, $ mn 84
Table 14. U.K. Ophthalmic Drug Delivery System Market by Setting, 2021-2031, $ mn 85
Table 15. France Ophthalmic Drug Delivery System Market by Product, 2021-2031, $ mn 87
Table 16. France Ophthalmic Drug Delivery System Market by Dosage Form, 2021-2031, $ mn 87
Table 17. France Ophthalmic Drug Delivery System Market by Setting, 2021-2031, $ mn 88
Table 18. Spain Ophthalmic Drug Delivery System Market by Product, 2021-2031, $ mn 90
Table 19. Spain Ophthalmic Drug Delivery System Market by Dosage Form, 2021-2031, $ mn 90
Table 20. Spain Ophthalmic Drug Delivery System Market by Setting, 2021-2031, $ mn 91
Table 21. Italy Ophthalmic Drug Delivery System Market by Product, 2021-2031, $ mn 93
Table 22. Italy Ophthalmic Drug Delivery System Market by Dosage Form, 2021-2031, $ mn 93
Table 23. Italy Ophthalmic Drug Delivery System Market by Setting, 2021-2031, $ mn 94
Table 24. Netherlands Ophthalmic Drug Delivery System Market by Product, 2021-2031, $ mn 96
Table 25. Netherlands Ophthalmic Drug Delivery System Market by Dosage Form, 2021-2031, $ mn 96
Table 26. Netherlands Ophthalmic Drug Delivery System Market by Setting, 2021-2031, $ mn 97
Table 27. Ophthalmic Drug Delivery System Market in Rest of Europe by Country, 2021-2031, $ mn 99
Table 28. Aero Pump GmbH: Company Snapshot 104
Table 29. Aero Pump GmbH: Business Segmentation 105
Table 30. Aero Pump GmbH: Product Portfolio 105
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the Market 23
2.2 Major Growth Drivers 25
2.3 Market Restraints and Challenges 29
2.4 Emerging Opportunities and Market Trends 32
2.5 Porter’s Fiver Forces Analysis 36
3 Segmentation of Europe Market by Product 40
3.1 Market Overview by Product 40
3.2 Pre-filled Syringes 42
3.3 Multidose Eyedroppers 43
3.4 Squeeze Dispensers 44
3.5 Mist Sprayers 45
3.6 Contact Lenses 46
3.7 Ocular Inserts 47
3.8 Intraocular Implants 48
3.9 Punctal Plugs 49
3.10 Other Products 50
4 Segmentation of Europe Market by Dosage Form 51
4.1 Market Overview by Dosage Form 51
4.2 Solutions 53
4.3 Gels 54
4.4 Ointments 55
4.5 Suspensions 56
4.6 Emulsions 57
4.7 Liposomes & Nanoparticles 58
5 Segmentation of Europe Market by Disease 59
5.1 Market Overview by Disease 59
5.2 Glaucoma 61
5.3 Diabetic Retinopathy 62
5.4 Cataract 63
5.5 Dry Eye Syndrome 64
5.6 Macular Degeneration 65
5.7 Diabetic Macular Edema 66
5.8 Refractive Issues 67
5.9 Other Diseases 68
6 Segmentation of Europe Market by Setting 69
6.1 Market Overview by Setting 69
6.2 Hospitals 71
6.3 Clinics 72
6.4 Homecare Settings 73
6.5 Ambulatory Surgical Centers (ASCs) 74
6.6 Other Settings 75
7 European Market 2021-2031 by Country 76
7.1 Overview of European Market 76
7.2 Germany 79
7.3 U.K. 83
7.4 France 86
7.5 Spain 89
7.6 Italy 92
7.7 Netherlands 95
7.8 Rest of European Market 98
8 Competitive Landscape 100
8.1 Overview of Key Vendors 100
8.2 New Product Launch, Partnership, Investment, and M&A 103
8.3 Company Profiles 104
Aero Pump GmbH 104
Allergan plc. 106
AptarGroup, Inc. 107
Becton, Dickinson and Company 108
Biocorp 109
Clearside Biomedical, Inc. 110
EyePoint Pharmaceuticals, Inc. 111
Gaplast GmbH 112
Gerresheimer AG 113
Jotteq Inc. 114
Kedalion Therapeutics, Inc. 115
Mati Therapeutics, Inc. 116
Nemera 117
Nipro Corporation 118
Ocular Therapeutix, Inc. 119
Ocumedic, Inc. 120
Owen Mumford 121
Re-Vana Therapeutics 122
Silgan Holdings Inc. 123
Terumo Corporation 124
Valeant Pharmaceuticals International Inc. (Bausch Health Company) 125
West Pharmaceutical Services, Inc. 126
RELATED REPORTS 127